Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HZL
|
|||
| Former ID |
DAP001077
|
|||
| Drug Name |
Trimeprazine
|
|||
| Synonyms |
Alimemazina; Alimemazine; Alimemazinum; Alimezine; Isobutrazine; Methylpromazine; Oxomemazin; Repetin; Teralen; Trimeperazine; Trimeprazine Tartrat; Bayer 1219; Alimemazina [INN-Spanish]; Alimemazine (INN); Alimemazine [INN:BAN]; Alimemazinum [INN-Latin]; Dl-Trimeprazine; Nedeltran (TN); Oxomemazine [DCF:INN]; Panectyl (TN); Repeltin (TN); Temaril (TN); Therafene (TN); Theralen (TN); Theralene (TN); Trimeprazine (BAN); Vallergan (TN); Vanectyl (TN); Trimeprazine 5,5-dioxide; Trimeprazine hemi-(+)-tartrate; N,N,beta-Trimethyl-10H-phenothiazine-10-propanamine; N,N,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine; N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine; (+-)-Alimemazine; (+-)-Trimeprazine; 10-(2-Methyl-3-dimethylaminopropyl)-phenothiazine; 10-(3-(Dimethylamino)-2-methylpropyl)phenothiazine; 10-(3-Dimethylamino-2-methylpropyl)phenothiazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Allergic rhinitis [ICD-11: CA08.0] | Approved | [1], [2] | |
| Therapeutic Class |
Antihistamines
|
|||
| Company |
Allergan Herbert Skin Care Div Allergan Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22N2S
|
|||
| Canonical SMILES |
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)CN(C)C
|
|||
| InChI |
1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3
|
|||
| InChIKey |
ZZHLYYDVIOPZBE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 84-96-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9381, 5664294, 7980834, 8153430, 10536926, 14998583, 26683957, 29224613, 46508449, 47662440, 48416667, 49698896, 50006469, 50543011, 51091464, 57244633, 57322852, 85209689, 92717845, 103216922, 103957784, 104309626, 125824456, 126621947, 126687442, 129976632, 134224850, 134338334, 134972661, 137120698, 141522740, 152102834, 160964578, 178103811, 179038167, 184534350, 198994073, 223441145, 223682819, 226408868, 241155290, 249924803
|
|||
| ChEBI ID |
CHEBI:9725
|
|||
| SuperDrug ATC ID |
R06AD01
|
|||
| SuperDrug CAS ID |
cas=000084968
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides ovatus was decreased by Trimeprazine tartrate (adjusted p-values: 3.35E-03). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides thetaiotaomicron was decreased by Trimeprazine tartrate (adjusted p-values: 3.25E-04). | |||
|
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides uniformis was decreased by Trimeprazine tartrate (adjusted p-values: 6.54E-04). | |||
|
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Bacteroides vulgatus was decreased by Trimeprazine tartrate (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Odoribacter splanchnicus was decreased by Trimeprazine tartrate (adjusted p-values: 6.97E-03). | |||
|
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides distasonis was decreased by Trimeprazine tartrate (adjusted p-values: 4.92E-05). | |||
|
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Parabacteroides merdae was decreased by Trimeprazine tartrate (adjusted p-values: 1.55E-06). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7237). | |||
| REF 2 | Drug information of Trimeprazine, 2008. eduDrugs. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.